3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
View Patent ↗The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula II, or a salt thereof, and a compound of formula VI or a salt thereof, wherein R 3 and R 4 as well as Act are as defined in the specification, and processes of manufacturing these. Additionally transformation of compounds (VI) with metallo organic compounds (VII) give rise to the new compounds (VIII) which are direct precursors for the preparation of Aliskiren.
1. A method for preparing a compound of formula (VIII)
wherein R 3 is C 1-7 alkyl or C 3-8 cycloalkyl; and R 4 is C 1-7 alkyl, C 2-7 alkenyl, C 3-8 cycloalkyl, phenyl- or naphthyl-C 1-4 alkyl, each unsubstituted or mono-, di-, or tri-substituted by C 1-4 alkyl, O—C 1-4 alkyl, OH, C 1-4 -alkylamino, di-C 1-4 -alkylamino, halogen, and/or trifluoromethyl; and
Act is an activating group selected from the group consisting of C 1-10 alkenyloxy-carbonyl, C 6-10 aryl-C 1-6 alkyl, C 1-6 alkyl-carbonyl, C 6-10 aryl-carbonyl, C 1-6 alkoxy-carbonyl, C 6-10 aryl-C 1-6 -alkoxycarbonyl, C 1-6 alkyl-sulfonyl, and C 6-10 aryl-sulfonyl, preferably, C 6-10 aryl-C 1-6 -alkoxycarbonyl, C 1-6 alkoxy-carbonyl, allyloxycarbonyl, and C 6-10 aryl-C 1-6 alkyl; R 1 is halogen, hydroxyl, C 1-6 halogenalkyl, C 1-6 alkoxy-C 1-6 alkyloxy or C 1-6 alkoxy-C 1-6 alkyl; R 2 is halogen, hydroxyl, C 1-4 alkyl, or C 1-4 alkoxy, or a salt thereof;
comprising the step of lactam ring opening of the N-activated lactam lactone of formula (VI) or a salt thereof
wherein R 3 , R 4 , and Act are as defined above;
with a compound of formula (VII)
wherein R 1 and R 2 are as defined above,
and wherein Y is a metal containing group such as —Li, —MgX, -magnesate, aryl magnesium species, alkyl magnesium species, —MnX, (alkyl) 3 MnLi—, or —CeX 2 wherein X is halogen, such as Cl, I, or Br, more preferably Br.
2. The method according to claim 1 wherein the N-activated lactam lactone of formula (VI) is reacted with a compound of the following formula:
3. A compound of formula (VIII)
wherein
R 3 is C 1-7 alkyl or C 3-8 cycloalkyl;
R 4 is C 1-7 alkyl, C 2-7 alkenyl, C 3-8 cycloalkyl, phenyl- or naphthyl-C 1-4 alkyl each unsubstituted or mono-, di- or tri-substituted by C 1-4 alkyl, O—C 1-4 alkyl, OH, C 1-4 alkylamino, di-C 1-4 alkylamino, halogen and/or by trifluoromethyl;
R 1 is halogen, hydroxyl, C 1-6 halogenalkyl, C 1-6 alkoxy-C 1-16 alkyloxy or C 1-6 alkoxy-C 1-6 alkyl;
R 2 is halogen, hydroxyl, C 1-4 alkyl or C 1-4 alkoxy; and
Act is an activating group selected from the group consisting of C 1-10 alkenyloxy-carbonyl, C 6-10 aryl-C 1-6 alkyl, C 1-6 alkyl-carbonyl, C 6-10 aryl-carbonyl, C 1-6 alkoxy-carbonyl, C 6-10 aryl-C 1-6 -alkoxycarbonyl, C 1-6 alkyl-sulfonyl, and C 6-10 aryl-sulfonyl, preferably, C 6-10 aryl-C 1-6 -alkoxycarbonyl, C 1-6 alkoxy-carbonyl, allyloxycarbonyl, and C 6-10 aryl-C 1-6 alkyl;
or a salt thereof.
4. The compound according to claim 3 , having the formula
5. The compound according to claim 3 , having the formula